Contrast Media Market 2019-2023 with GE Healthcare, Daiichi, Bayer Healthcare Pharmaceuticals, AMAG Pharmaceuticals, NanoScan Imaging, Medrad Inc, Targeson, Guerbet Etc.

Global Contrast Media Market - Key Players

GE Healthcare (US), Daiichi (Japan), Bayer Healthcare Pharmaceuticals (Germany), AMAG Pharmaceuticals (US), NanoScan Imaging (US), Medrad Inc (US), Targeson (US), Guerbet (Japan), Bracco Diagnostic Inc. (Italy), Guerbet Group (France), Covidien (Ireland), Lantheus Medical Imaging (U.S.), ), Bracco Imaging S.p.A. (Italy), Subhra Pharma Private Limited (India), nanoPET Pharma GmbH (Germany), CMC Contrast AB (Sweden), Mallinckrodt Pharmaceuticals (UK)

Global Contrast Media Market - Segmentation

By type, the Market for Contrast Media has been segmented into intravenous contrast materials, iodine-based, and, other.

By procedures, the market has been segmented into X-ray, computed tomography, magnetic resonance imaging, ultrasound, and, other.

By application, the global contrast media has been segmented into X-ray, computed tomography, magnetic resonance imaging, ultrasound, and, other.

Get Sample Report @ https://www.marketresearchfuture.com/sample_request/1284

Global Contrast Media Market - Insights

The threats associated with the rise in the number of patients suffering from chronic diseases are propelling growth in the contrast media market. According to the latest report published by Market Research Future (MRFR), the Contrast Media Market will grow extensively throughout the forecast period with a CAGR of 6.3%.

The major driver of the market acceleration is the wide range of imaging tests that fuel the demand for contrast media. The imaging tests such as Magnetic Resonance Imaging (MRI), x-rays, Computed Tomography (CT), etc. have become an inevitable part of the diagnosis for most of the diseases. The large-scale penetration of imaging technology in healthcare has catalyzed the demand for contrast media in the market. The incidences of cardiovascular diseases, cancer, etc. have been on a steep rise which creates a need for the availability of better healthcare imaging tests. In 2012, the U.S. witnessed an inclusion of 14.1 Million new cancer patients with the death count of cancer patients reaching a mark of 8.2 Million.

The regulatory initiatives taken by the government in checking the health hazards related to residue amount of contrast media in body restricts the market to some extent but also opens up avenues for new inventions and discoveries. Some of the other factors that might hinder market growth are rising awareness about adverse effects, clinical trials for alternative methods, etc.

Competitive Analysis:

GE Healthcare an American multinational company headquartered in the U.S., is one of the leading players in the contrast medium market with manufacturing and distribution of diagnostic imaging agents with more than 100 countries. OMNISCAN and VISIPAQUE are the major products of the company. Recently in March 2017, the company showcased its MRI contrast media product range at the European Congress of Radiology (ECR) 2017 meeting by launching Clariscan, which is a macrocyclic agent and is a gadolinium-based contrast agent (GBCA). Clariscan is intended to support effective visualization of abnormalities in the brain, spine, and associated tissues. The launch of this product will be provided alongside GE Healthcare’s comprehensive support services and solutions to healthcare physicians across the globe. The demand for contrast media has altogether expanded over the previous decade because of increasing advancement in procedures in MR imaging, raising the significance of uninterrupted and sustainable product supply, and in addition meeting the individual needs of patients undergoing diagnostic techniques. Knowing the demand for contrast medium, GE healthcare invested over USD 65 million in its overall supply across the globe from 2013 and 2016, to increase its manufacturing capacity. GE contrast media products are utilized as a part of more than 70 million systems for every year, identical to infusion in two patients for each second. In 2015, 62 million patients diagnosed using GE contrast media and acquired major share for the global contrast media market.

Daiichi a global pharmaceutical company and the second largest pharmaceutical company headquartered in Japan. Sonazoid an ultrasound contrast medium is widely used product of the company. In 2014, company has acquired Ambit Biosciences.

Bayer Healthcare Pharmaceuticals Inc. is headquartered in Germany. It is a multinational chemical, pharmaceutical, and life sciences company. In April 2016, the company announced the approval of, Gadavist injection that is the first contrast agent used with magnetic resonance angiography. Gadavist MRA significantly improved the visualization, or assess ability when compared to unenhanced MRA. This approval of the advanced product will enhance the revenue growth which will further boost the growth of the market. Ultravist, Eovist and Magnevist are the some of the major products of the company.

Industry News:

In November 2018, the U.S. Food and Drug Administration (FDA) approved the clinical use of a magnetic resonance imaging (MRI) scanner which allows spotting pituitary tumors in crushing's patients. The new ultra-high field 7T Terra MRI scanner allows more reliable images of the brain and facilitates identification of very small tumors which standard MRI fails to spot.

In October 2018, Israeli startup iNNOGING innovated breakthrough in sonography technology. The innovation will enable physicians to manipulate captured ultrasound video and allow virtual dynamic examination by conversion of the video clip into a 3D model without the presence of the patient.

Global Contrast Media Market - Regional Analysis

By region, the market has been segmented into North America, Europe, Asia, and, Middle East & Africa. The investments and developments have been multiplying in North America market which when coupled with the presence of established healthcare services providers are the key drivers responsible for catalyzing the expansion of the market. The demand for better healthcare facilities, initiatives taken by government institutions such as FDA (U.S. Food and Drug Administration), escalating prevalence of devices requiring imaging technologies, etc. are also stimulating revenue generation from the region. The rising count of cancer patients has intensified a fear among the population leading to an increase in pre-diagnosis treatments which is expected to escalate the demand in the market throughout the projection period.

Browse Complete 80 Pages Premium Research Report Enabled with Tables and Figures @ https://www.marketresearchfuture.com/reports/contrast-media-market-1284

Europe market accounts for the second largest share of the global market. The increased expenditure in healthcare, growing awareness about diseases, availability of efficient healthcare services, etc. have led to development in revenue generation from the market. An increase in the incidence of gastrointestinal diseases has also catalyzed the expansion of the market in the region. Asia Pacific region trails Europe and will be the fastest growing market during the projection period. The huge population base of Asia is the key market growth driver. Other factors responsible for the growth in this region are developments in the healthcare sector, increased awareness and healthcare spending, large-scale penetration by major market players, etc. The rising demand will infuse growth in Middle East & Africa market.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: salesteam@marketresearchfuture.com

This release was published on openPR.